Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
Authors
Keywords
Immunotherapy, PD-1, PD-L1, CTLA-4, OX-40, Biomarkers
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 1, Pages 1-9
Publisher
Springer Nature
Online
2018-12-18
DOI
10.1007/s00262-018-2285-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer
- (2018) Kaushal Parikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination
- (2018) Tyler W. Hulett et al. Journal for ImmunoTherapy of Cancer
- Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017
- (2018) Michele Maio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
- (2017) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
- (2017) Giuseppe V. Masucci et al. Journal of Translational Medicine
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Report on the Third FDA–AACR Oncology Dose-Finding Workshop
- (2017) Leisha A. Emens et al. Cancer Immunology Research
- Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
- (2017) Rajeev K. Shrimali et al. Cancer Immunology Research
- ‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization
- (2017) Markus Müller et al. Frontiers in Immunology
- Systematic evaluation of immune regulation and modulation
- (2017) David F. Stroncek et al. Journal for ImmunoTherapy of Cancer
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- (2017) Sacha Gnjatic et al. Journal for ImmunoTherapy of Cancer
- A Combinatory Antibody–Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries
- (2017) Nina Persson et al. PLoS One
- Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
- (2016) Aaron R. Hansen et al. CANCER RESEARCH
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Mass spectrometry-based antigen discovery for cancer immunotherapy
- (2016) Michal Bassani-Sternberg et al. CURRENT OPINION IN IMMUNOLOGY
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome
- (2016) Satyendra C. Tripathi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy
- (2015) E. Zsiros et al. CLINICAL CANCER RESEARCH
- CCR 20th Anniversary Commentary: Autologous T Cells--The Ultimate Personalized Drug for the Immunotherapy of Human Cancer
- (2015) S. A. Rosenberg CLINICAL CANCER RESEARCH
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
- (2013) C. L.-L. Chiang et al. CLINICAL CANCER RESEARCH
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
- (2011) L. H. Butterfield et al. CLINICAL CANCER RESEARCH
- An automated analysis of highly complex flow cytometry-based proteomic data
- (2011) Jan Stuchlý et al. CYTOMETRY PART A
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search